Kynam Capital Management, L.P. is an investment fund managing more than $955 billion ran by Jared Keller. There are currently 22 companies in Mr. Keller’s portfolio. The largest investments include Natera Inc and Celldex Therapeutics, together worth $344 billion.
As of 7th August 2024, Kynam Capital Management, L.P.’s top holding is 2,014,408 shares of Natera Inc currently worth over $218 billion and making up 22.8% of the portfolio value.
Relative to the number of outstanding shares of Natera Inc, Kynam Capital Management, L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 3,388,967 shares of Celldex Therapeutics worth $125 billion, whose value fell 8.2% in the past six months.
The third-largest holding is Syndax Pharmaceuticals Inc worth $117 billion and the next is Dynavax Technologies worth $79.5 billion, with 7,082,562 shares owned.
Currently, Kynam Capital Management, L.P.'s portfolio is worth at least $955 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Kynam Capital Management, L.P. office and employees reside in Princeton, New Jersey. According to the last 13-F report filed with the SEC, Jared Keller serves as the COO at Kynam Capital Management, L.P..
In the most recent 13F filing, Kynam Capital Management, L.P. revealed that it had opened a new position in
Burning Rock Biotech Ltd and bought 974,668 shares worth $6.28 billion.
The investment fund also strengthened its position in Natera Inc by buying
14,408 additional shares.
This makes their stake in Natera Inc total 2,014,408 shares worth $218 billion.
Natera Inc soared 109.1% in the past year.
On the other hand, there are companies that Kynam Capital Management, L.P. is getting rid of from its portfolio.
Kynam Capital Management, L.P. closed its position in Burning Rock Biotech Ltd on 14th August 2024.
It sold the previously owned 9,640,914 shares for $7.02 billion.
Jared Keller also disclosed a decreased stake in Protagonist Therapeutics Inc by 0.3%.
This leaves the value of the investment at $27.7 billion and 800,000 shares.
The two most similar investment funds to Kynam Capital Management, L.P. are Seven Eight Capital, L.P. and Td Capital Management. They manage $955 billion and $955 billion respectively.
Kynam Capital Management, L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 84.3% of
the total portfolio value.
The fund focuses on investments in the United States as
50.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.55 billion.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Natera Inc |
0.72%
2,014,408
|
$218,140,242,000 | 22.84% |
| Celldex Therapeutics Inc. |
16.86%
3,388,967
|
$125,425,669,000 | 13.13% |
| Syndax Pharmaceuticals Inc |
1.10%
5,722,057
|
$117,473,830,000 | 12.30% |
| Dynavax Technologies Corp. |
67.05%
7,082,562
|
$79,537,171,000 | 8.33% |
| Cogent Biosciences, Inc. |
8.95%
9,260,385
|
$78,065,046,000 | 8.17% |
| Vaxcyte, Inc. |
1.11%
753,240
|
$56,877,152,000 | 5.95% |
| Vera Therapeutics Inc |
1.11%
1,543,669
|
$55,849,944,000 | 5.85% |
| Biocryst Pharmaceuticals Inc. |
35.22%
8,826,710
|
$54,549,068,000 | 5.71% |
| Protagonist Therapeutics Inc |
30.08%
800,000
|
$27,720,000,000 | 2.90% |
| 2seventy Bio Inc |
No change
5,953,825
|
$22,922,226,000 | 2.40% |
| Viridian Therapeutics Inc |
1,207.17%
1,750,000
|
$22,767,500,000 | 2.38% |
| Wave Life Sciences Ltd. |
1.10%
3,975,521
|
$19,837,850,000 | 2.08% |
| Travere Therapeutics Inc |
1.08%
2,021,659
|
$16,618,037,000 | 1.74% |
| Liquidia Corp |
59.23%
916,574
|
$10,998,888,000 | 1.15% |
| Ironwood Pharmaceuticals Inc |
1.04%
1,641,891
|
$10,705,129,000 | 1.12% |
| Tyra Biosciences Inc |
10.00%
566,715
|
$9,061,773,000 | 0.95% |
| Amarin Corp Plc |
1.11%
12,155,830
|
$8,363,211,000 | 0.88% |
| Burning Rock Biotech Ltd |
Closed
9,640,914
|
$7,019,549,000 | |
| Burning Rock Biotech Ltd |
Opened
974,668
|
$6,283,880,000 | 0.66% |
| Sutro Biopharma Inc |
1.10%
2,023,683
|
$5,929,391,000 | 0.62% |
| Acelyrin Inc |
109.73%
831,310
|
$3,666,077,000 | 0.38% |
| Caribou Biosciences Inc |
54.11%
1,646,702
|
$2,700,591,000 | 0.28% |
| Cg Oncology Inc |
Opened
53,911
|
$1,701,970,000 | 0.18% |
| No transactions found | |||
| Showing first 500 out of 23 holdings | |||